EP4259626C0 - PROCESS FOR PREPARING 4-(3,5-DIFLUOROPHENYL)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1 OCTAN-8-YL)6,7-DIHYDRO-5H-[1,2,4 TRIAZOLO[1,5-A PYRIMIDIN-2-AMIN - Google Patents
PROCESS FOR PREPARING 4-(3,5-DIFLUOROPHENYL)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1 OCTAN-8-YL)6,7-DIHYDRO-5H-[1,2,4 TRIAZOLO[1,5-A PYRIMIDIN-2-AMINInfo
- Publication number
- EP4259626C0 EP4259626C0 EP21835211.0A EP21835211A EP4259626C0 EP 4259626 C0 EP4259626 C0 EP 4259626C0 EP 21835211 A EP21835211 A EP 21835211A EP 4259626 C0 EP4259626 C0 EP 4259626C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- methylpyrimidin
- octan
- amin
- triazolo
- azabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/04—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020135294 | 2020-12-10 | ||
| PCT/EP2021/084734 WO2022122800A1 (en) | 2020-12-10 | 2021-12-08 | Process for the preparation 4-(3,5-difluorophenyl)-n-[3-(6-methylpyrimidin-4-yl)-3- azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP4259626A1 EP4259626A1 (en) | 2023-10-18 |
| EP4259626C0 true EP4259626C0 (en) | 2025-01-29 |
| EP4259626B1 EP4259626B1 (en) | 2025-01-29 |
Family
ID=79171263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21835211.0A Active EP4259626B1 (en) | 2020-12-10 | 2021-12-08 | Process for the preparation 4-(3,5-difluorophenyl)-n-[3-(6-methylpyrimidin-4-yl)-3- azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240025911A1 (en) |
| EP (1) | EP4259626B1 (en) |
| JP (1) | JP7837977B2 (en) |
| KR (1) | KR20230118099A (en) |
| CN (1) | CN116568298A (en) |
| AR (1) | AR124195A1 (en) |
| AU (1) | AU2021393922A1 (en) |
| BR (1) | BR112023011020A2 (en) |
| CA (1) | CA3202551A1 (en) |
| IL (1) | IL303354A (en) |
| MX (1) | MX2023006712A (en) |
| TW (1) | TW202237613A (en) |
| WO (1) | WO2022122800A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| AR109829A1 (en) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | BRIDGED PIPERIDINE DERIVATIVES |
| EP3523304B1 (en) | 2016-10-04 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bicyclic heteroaryl derivatives |
| US11319314B2 (en) * | 2016-11-08 | 2022-05-03 | Hoffmann-La Roche Inc. | Phenoxytriazoles |
| US11370802B2 (en) | 2018-01-22 | 2022-06-28 | Hoffmann-La Roche, Inc. | Triazolo-azepine derivatives |
-
2021
- 2021-12-08 EP EP21835211.0A patent/EP4259626B1/en active Active
- 2021-12-08 CA CA3202551A patent/CA3202551A1/en active Pending
- 2021-12-08 KR KR1020237019262A patent/KR20230118099A/en active Pending
- 2021-12-08 WO PCT/EP2021/084734 patent/WO2022122800A1/en not_active Ceased
- 2021-12-08 BR BR112023011020A patent/BR112023011020A2/en not_active Application Discontinuation
- 2021-12-08 IL IL303354A patent/IL303354A/en unknown
- 2021-12-08 JP JP2023535379A patent/JP7837977B2/en active Active
- 2021-12-08 MX MX2023006712A patent/MX2023006712A/en unknown
- 2021-12-08 CN CN202180082474.3A patent/CN116568298A/en active Pending
- 2021-12-08 US US18/256,629 patent/US20240025911A1/en active Pending
- 2021-12-08 AU AU2021393922A patent/AU2021393922A1/en not_active Abandoned
- 2021-12-09 TW TW110146011A patent/TW202237613A/en unknown
- 2021-12-09 AR ARP210103411A patent/AR124195A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021393922A9 (en) | 2024-02-08 |
| MX2023006712A (en) | 2023-06-20 |
| CN116568298A (en) | 2023-08-08 |
| KR20230118099A (en) | 2023-08-10 |
| WO2022122800A1 (en) | 2022-06-16 |
| US20240025911A1 (en) | 2024-01-25 |
| AR124195A1 (en) | 2023-02-22 |
| BR112023011020A2 (en) | 2024-01-30 |
| CA3202551A1 (en) | 2022-06-16 |
| JP2023553941A (en) | 2023-12-26 |
| TW202237613A (en) | 2022-10-01 |
| JP7837977B2 (en) | 2026-03-31 |
| EP4259626B1 (en) | 2025-01-29 |
| EP4259626A1 (en) | 2023-10-18 |
| AU2021393922A1 (en) | 2023-06-15 |
| IL303354A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4206186A4 (en) | Preparation method for 1,5-pentane diisocyanate | |
| MX2011001679A (en) | Flavin derivatives. | |
| DE602006021645D1 (en) | Process and intermediates for the preparation of N4-phenyl quinazoline-4-amine derivatives | |
| EA201001238A1 (en) | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | |
| EA200702347A1 (en) | METHOD FOR OBTAINING GLUCOPYRANOSYLESE-SUBSTITUTED DERIVATIVES OF BENZILBENZENE AND INTERMEDIATE PRODUCTS FOR THEIR OBTAINING | |
| PH12015500275A1 (en) | Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same | |
| MX2012008911A (en) | SALTS AND POLYMORPHES OF 8-FLUORO-2- {4 - [(METHYLAMINE) METHYL] PHENYL} -1,3, 4,5-TETRAHYDRO-6H-ACEPINO [5,4,3-CD] INDOL-6-ONA. | |
| EA201100748A1 (en) | PYRAZINE COMPOUNDS AS PHOSPHODESTERASE INHIBITORS 10 | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| TW200621256A (en) | Formulations | |
| DE602007003375D1 (en) | PROCESS FOR PREPARING 3 (R) - (2-HYDROXY-2,2-DITHIEN-2-YLACETOXY) -1- (3-PHENOXYPROPYL) -1-AZONIABICYCLOE2.2.2ÜOCTANBROMIDE | |
| WO2018029711A3 (en) | Process for the preparation of venetoclax | |
| EP4317353A4 (en) | POLISHING COMPOSITION, METHOD FOR PREPARING THE POLISHING COMPOSITION AND POLISHING METHOD | |
| NO20082425L (en) | Formulations comprising jorumycin, reni-eramycin, safracin or saframycin-related compounds for the treatment of proliferative diseases | |
| EP3953339C0 (en) | PROCESS FOR PREPARING 1-DEOXY-1-METHYLAMINO-D-GLUCITOL-2-(3,5-DICHLOROPHENYL)-6-BENZOXAZOLE CARBOXYLATE | |
| MX394391B (en) | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | |
| ATE411994T1 (en) | PREPARATION OF A HIGH PURITY SUBSTITUTED QUINOXALINE | |
| MX388697B (en) | THIAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE. | |
| TW201612169A (en) | (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders | |
| DE602005014280D1 (en) | PROCESS FOR THE PREPARATION OF Ä1,4,5Ü-OXADIAZEPINE DERIVATIVES | |
| DE502005000428D1 (en) | Process for the preparation of 1,2-diaminocyclohexane-platinum (II) complexes | |
| TW200617011A (en) | Process for preparing quinoline compounds and products obtained therefrom | |
| DE502006004524D1 (en) | PROCESS FOR THE PREPARATION OF 3,7-DIAZA BICYCLOÄ3.3.1ÜNONAN COMPOUNDS | |
| DE60315308D1 (en) | PROCESS FOR PREPARING 5- (4-FLUORPHENYL) -1-i2 - ((2R, 4R) -4-HYDROXY-6-OXOTETRAHYDROPYRAN-2-YL) ETHYLO-2-ISOPROPYL-4-PHENYL-1H-PYRROL-3 -CARBONSÄUREPHENYLAMID | |
| EP3902790C0 (en) | IMPROVED PROCESS FOR THE PREPARATION OF 4,6-DIHYDROXYPYRIMIDINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230710 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20240813 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602021025592 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20250129 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250129 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250129 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250529 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250129 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250129 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250129 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250129 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: L10 Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20251210 |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 5 Effective date: 20251119 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: U11 Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260101 |
|
| 26N | No opposition filed |
Effective date: 20251030 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20251119 Year of fee payment: 5 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20260101 Year of fee payment: 5 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250129 |
|
| U1H | Name or address of the proprietor changed after the registration of the unitary effect |
Owner name: F. HOFFMANN-LA ROCHE AG; CH |